APOSCREEN-1 – a prospective, single-arm clinical trial for the implementation of a pharmacy-based screening for cardiovascular-kidney-metabolic risk factors in Schleswig-Holstein

Eric Amelunxen, Amelie Kokot, Benedikt Kolbrink, Sarah-Yasmin Thomsen, Maja L. Meßtorff, Matthias Laudes, Kenny R. Lienhard, Lucas M. Bachmann, Laura K. Sievers, Roland Schmitt, Kevin Schulte, Friedrich A. von Samson-Himmelstjerna · 2026

Read APOSCREEN-1 – a prospective, single-arm clinical trial for the implementation of a pharmacy-based screening for cardiovascular-kidney-metabolic risk factors in Schleswig-Holstein by Eric Amelunxen, Amelie Kokot, Benedikt Kolbrink, Sarah-Yasmin Thomsen, Maja L. Meßtorff, Matthias Laudes, Kenny R. Lienhard, Lucas M. Bachmann, Laura K. Sievers, Roland Schmitt, Kevin Schulte, Friedrich A. von Samson-Himmelstjerna (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13244955.txt.

Description

Eric Amelunxen and colleagues test whether community pharmacies can catch heart, kidney, and metabolic risk earlier than clinics do. Their trial protocol appeared in BMC Nephrology in 2026. The APOSCREEN-1 study runs in twenty pharmacies in Germany's Schleswig-Holstein state. One thousand adults aged forty and over who meet risk criteria get point-of-care testing on the spot: glycated hemoglobin, blood lipids, urine albumin, and blood pressure, plus a clinical history.

Results flow to a study center through an online platform. Anyone crossing thresholds is sent for confirmatory laboratory testing at the center or their general practitioner. The trial's main questions are practical: will people accept screening at the pharmacy counter, and how much undetected disease it finds? Primary-care screening uptake is low, and the syndrome often surfaces only after organ damage. If pharmacies prove feasible and high-yield, they offer an accessible front door to prevention.

Catalog record

CREATOREric Amelunxen, Amelie Kokot, Benedikt Kolbrink, Sarah-Yasmin Thomsen, Maja L. Meßtorff, Matthias Laudes, Kenny R. Lienhard, Lucas M. Bachmann, Laura K. Sievers, Roland Schmitt, Kevin Schulte, Friedrich A. von Samson-Himmelstjerna
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE42 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13244955

Browse the full library · About the Tower of Babel